Coated recombinant target protein helps explore IL-1RAP CAR T-cell functionality in vitro.
Abstract
Many chimeric antigen receptor (CAR) T-cell therapies are being developed to treat various cancers. Five such therapies have been approved by regulatory agencies for blood cancers unresponsive to other treatments, such as B-cell acute lymphoid leukemia [1], B-lymphoma (diffuse large B-cell [2] and mantle cell lymphoma [3]), and multiple myeloma [4]. These therapies must be subjected to robust quality controls to ensure the safety of each batch and the final product. Considering high inter-donor or patient variability, a quality control strategy would help the Advanced Therapy Medicinal Product (ATMP) manufacturers to optimize and standardize their manufacturing processes, guaranteeing their reproducibility [5]. We need to quantify the potency of CAR T-cells using validated assays and good laboratory practices (GLP) before entering into pilot clinical trials (phase 3) to register for the ATMP.
| Authors: | Da Rocha MN, Guiot M, Nicod C, Trad R, Bouquet L, Haderbache R, Warda W, Baurand PE, Jouanneau C, Dulieu P, Deschamps M, Ferrand C, |
|---|---|
| Journal: | Immunol Res; 2023 Apr;71(2):276-282 doi:10.1007/s12026-022-09348-y |
| Year: | 2023 |
| PubMed: | PMID: 36456721 (Go to PubMed) |